Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 8/20 | 0.45 |
| ▸ | CA2 | P00918 | 8/20 | 0.45 |
| ▸ | CA12 | O43570 | 7/20 | 0.45 |
| ▸ | CA9 | Q16790 | 7/20 | 0.45 |
| ▸ | FYN | P06241 | 10/20 | 0.44 |
| ▸ | CA3 | P07451 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | CA6 | P23280 | 4/20 | 0.43 |
| ▸ | CA5A | P35218 | 4/20 | 0.43 |
| ▸ | CA7 | P43166 | 4/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | GRK5 | P34947 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2978971 | 0.90 | MEN1 (0.47) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2977105 | 0.88 | MEN1 (0.43) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2970467 | 0.87 | CA1 (0.42) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2979751 | 0.87 | FYN (0.50) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2985686 | 0.86 | CA1 (0.46) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2981229 | 0.86 | CA12 (0.48) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2981853 | 0.86 | CA12 (0.48) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2983702 | 0.86 | CA12 (0.48) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2983366 | 0.86 | CA2 (0.48) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2977197 | 0.85 | CA12 (0.52) | MEN1KMT2ACA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170097334-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-06 | — | — | US | claimed |
| US-20160115518-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-28 | — | — | US | claimed |
| US-20110263554-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | WARF - WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-10-27 | — | — | US | claimed |
| WO-2010053573-A2 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | KAWAOKA YOSHIHIRO (US) | 2010-05-14 | — | — | WO | claimed |
| US-20050069492-A1 | Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides | PHARMASCIENCE INC. (CA) | 2005-03-31 | — | — | US | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240400983-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240392241-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2024171957-A1 | TRANSPLANTATION OF PITUITARY HORMONE-PRODUCING CELLS | 国立大学法人東海国立大学機構 | 2024-08-22 | — | — | WO | disclosed |
| EP-4410963-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | Sumitomo Chemical Company, Limited (JP) | 2024-08-07 | — | — | EP | disclosed |
| US-20070238766-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-10-11 | — | — | US | disclosed |
| US-7230019-B2 | Imidazo [2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-06-12 | — | — | US | disclosed |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-04-19 | — | — | US | disclosed |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20050069492-A1 | Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides | PHARMASCIENCE INC. (CA) | 2005-03-31 | — | — | US | disclosed |
| EP-1463735-A1 | IMIDAZO[2,1-B]-1,3,4-THIADIAZOLE SULFONAMIDES | Aegera Therapeutics Inc. (CA) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003051890-A1 | IMIDAZO [2,1-B]-1,3,4-THIADIAZOLE SUFLONAMIDES | AEGERA THERAPEUTICS INC. (CA) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | MEN1 1150/4885KMT2A 723/4885CA1 4727/4885 |
| US-20160115518-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | ZC3HAV1, WASF2, ZC3HAV1L | MEN1 2749/4885KMT2A 3879/4885CA1 4808/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | MEN1 1475/4885KMT2A 445/4885CA1 4837/4885 |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | MEN1 3572/4885KMT2A 3862/4885CA1 748/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | MEN1 1822/4885KMT2A 1324/4885CA1 4522/4885 |
| US-20110263554-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | ZC3HAV1, WASF2, ZC3HAV1L | MEN1 2619/4885KMT2A 3882/4885CA1 4821/4885 |
| US-20170097334-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | ZC3HAV1, WASF2, ZC3HAV1L | MEN1 2749/4885KMT2A 3879/4885CA1 4808/4885 |
| US-20070238766-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | MEN1 3572/4885KMT2A 3862/4885CA1 748/4885 |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | MEN1 3572/4885KMT2A 3862/4885CA1 748/4885 |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | MEN1 3572/4885KMT2A 3862/4885CA1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.